검색어: milbemycin (영어 - 크로아티아어)

milbemycin oxime
milbemicin oksim

milbemycin oxime (mg)
milbemicin oksim (mg)

afoxolaner / milbemycin oxime
afoksolaner / milbemicin oksim

afoxolaner / milbemycin oxime tablets
afoxolaner / milbemycin oxime tablete

milbemycin oxime acts as an ‘endoparasiticide’.
milbemicin oksim djeluje kao „ektoparasiticid“.

atcvet code: qp54ab51 (milbemycin combinations).
atcvet kod: qp54ab51 (kombinacije milbemicina).

pharmacotherapeutic group: antiparasitic products, endectocides, milbemycin combinations.
farmakoterapijska skupina: antiparazitski proizvod, endektocid, milbemicin kombinacije.

milbemycin oxime is an antiparasitic endectocide belonging to the macrocyclic lactones.
milbemicin oksim je antiparazitski endektocid koji spada u grupu makrocikličkih laktona.

milbemycin oxime acts by disrupting the glutamate neuro-transmission in invertebrates.
milbemicin oksim djeluje na način da ometa neurotransmisiju reguliranu glutamatima kod beskralježnjaka.

milbemycin oxime increases glutamate binding with consequent enhanced chloride ion flow into the cell.
povećava vezanje glutamata sa posljedičnim povećanim protokom iona klora u stanicu.

milbemycin oxime plasma concentrations and some pharmacokinetic parameters are increased in the presence of spinosad.
koncentracije milbemicin oksima u plazmi i neki farmakokinetički parametri povećani su u prisutnosti spinosada.

the worm study showed trifexis to have the same level of effectiveness against gut worms as milbemycin oxime.
ispitivanje crva pokazalo je da trifexis ima istu razinu djelotvornosti protiv crijevnih crva kao milbemicin oksim.

in clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime.
tijekom kliničkih studija nisu zamijećene ozbiljnije nuspojave pridružene kombinaciji afoksolanera i milbemicin oksima.

monthly repeated oral administration of spinosad and milbemycin oxime over six months revealed evidence of spinosad and milbemycin oxime accumulation in juvenile dogs.
ponovljena mjesečna peroralna primjena spinosada i milbemicin oksima tijekom šest mjeseci otkrila je nakupljanje spinosada i milbemicin oksima kod mladih pasa.

the field study for gut worms showed that nexgard spectra was effective in reducing gut worms and was at least as effective as the milbemycin oxime and praziquantel.
terenskim ispitivanjem za gastrointestinalne crve utvrđeno je da je vmp nexgard spectra bio podjednako djelotvoran u smanjivanju crva te da je bio barem podjednako djelotvoran kao milbemicin oksim i prazikvantel.

for gut worms a field study involved 408 dogs with natural infections that were given either a single treatment with nexgard spectra or a medicine containing milbemycin oxime and praziquantel.
u slučaju gastrointestinalnih crva, terenskim ispitivanjem obuhvaćeno je 408 pasa s prirodnim infekcijama koji su primili jednu terapiju vmp-om nexgard spectra ili vmp-om koji je sadržavao milbemicin oksim i prazikvantel.

the excretion of milbemycin oxime in lactating dogs (bitches) has not been tested and the safety for suckling puppies has not been established.
izlučivanje milbemicin oksima kod kuja koje doje nije ispitano te nije utvrđena neškodljivost za štence koji sišu.

after oral administration of 45 mg spinosad and 0.75 mg milbemycin oxime/kg bodyweight to fed dogs, spinosyns a and d are rapidly absorbed and extensively distributed.
nakon peroralne primjene 45 mg spinosada i 0,75 mg milbemicin oksima po kg tjelesne težine kod sitih pasa, spinosini a i d brzo se apsorbiraju i široko raspodjeljuju.

in adult dogs, after repeated oral administration of spinosad and milbemycin oxime for six consecutive months, increases in elimination half-lives were observed up to month 3.
kod odraslih pasa, nakon ponovljene peroralne primjene spinosada i milbemicin oksima tijekom šest uzastopnih mjeseci primijećeno je povećanje poluvremena eliminacije do 3 mjeseca.

milbemycin oxime is a systemic macrocyclic lactone containing two major factors, a3 and a4 (ratio of a3:a4 is 20:80).
milbemicin oksim je sustavni makrociklički lakton koji sadrži dva glavna faktora, a3 i a4 (omjer a3:a4 je 20:80).